INTELLIA THERAPEUTICS INC Receives Mixed Ratings from Gurus

A report indicates that INTELLIA THERAPEUTICS INC shows a mixed performance according to established guru strategies. While it excels in certain areas, it fails to meet key growth criteria, presenting investors with potential risks and opportunities moving forward.

Date: 12-09-2024

AI Rating: 5

In the latest report, INTELLIA THERAPEUTICS INC (NTLA) has been rated based on the strategies of Benjamin Graham, emphasizing a value-investing approach. The stock has received a score of 43%, indicating it doesn't meet the expectations of the strategy, which typically considers a score of 80% or above as favorable.

The evaluation highlights that INTELLIA passed in several areas such as Sector, Current Ratio, and Long-Term Debt in Relation to Net Current Assets. These metrics are generally favorable and suggest that the company is managing its financial obligations well.

However, the report notes critical failures in key performance metrics: Sales, Long-Term EPS Growth, P/E Ratio, and Price/Book Ratio. This is a significant concern as it indicates that the stock may not exhibit the growth potential that many investors seek. The failure in sales and growth metrics can negatively affect overall investor sentiment, leading to decreased stock valuations.

For the stock's performance, these mixed results could present significant risks. The low score in earnings growth and price-to-earnings ratio indicates potential underperformance compared to industry peers. Investors should be cautious, as these factors could lead to fluctuations in stock price and overall market perception.

Stocks: NTLA